Published November 04, 2012; Updated September 12, 2014
Susa Coffey, MD
Selected Reference
6. Nichols G, Lazzrin A, Maggiolo F, et al. Phase 3 assessment of dolutegravir (DTG) 50mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled. In: Program and abstracts of the 7th International Antiviral Society Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur. Abstract TULBPE19.